BioPharmX Corporation, a specialty pharmaceutical company, announced that research being presented at the 2016 Winter Clinical Dermatology Conference shows its unique formulation of minocycline, known as BPX-01, may offer a

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In